Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Abstract

OBJECTIVE: It is important to analyze and track Epidermal Growth Factor Receptor (EGFR) mutation status for predicting efficacy and monitoring resistance throughout EGFR-tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) patients. The objective of this study was to determine the feasibility and predictive utility of EGFR mutation detection in peripheral blood. METHODS: Plasma, serum and tumor tissue samples from 164 NSCLC patients were assessed for EGFR mutations using Amplification Refractory Mutation System (ARMS). RESULTS: Compared with matched tumor tissue, the concordance rate of EGFR mutation status in plasma and serum was 73.6% and 66.3%, respectively. ARMS for EGFR mutation detection in blood showed low sensitivity (plasma, 48.2%; serum, 39.6%) but high specificity (plasma, 95.4%; serum, 95.5%). Treated with EGFR-TKIs, patients with EGFR mutations in blood had significantly higher objective response rate (ORR) and insignificantly longer progression-free survival (PFS) than those without mutations (ORR: plasma, 68.4% versus 38.9%, P = 0.037; serum, 75.0% versus 39.5%, P = 0.017; PFS: plasma, 7.9 months versus 6.1 months, P = 0.953; serum, 7.9 months versus 5.7 months, P = 0.889). In patients with mutant tumors, those without EGFR mutations in blood tended to have prolonged PFS than patients with mutations (19.7 months versus 11.0 months, P = 0.102). CONCLUSIONS: EGFR mutations detected in blood may be highly predictive of identical mutations in corresponding tumor, as well as showing correlations with tumor response and survival benefit from EGFR-TKIs. Therefore, blood for EGFR mutation detection may allow NSCLC patients with unavailable or insufficient tumor tissue the opportunity to benefit from personalized treatment. However, due to the high false negative rate in blood samples, analysis for EGFR mutations in tumor tissue remains the gold standard.

Introduction

Lung cancer is the leading cause of cancer-related death worldwide [1]. Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, of which more than 70% are initially diagnosed with unresectable advanced disease [2,3]. Systemic treatment, including molecular-targeted therapy, plays a central role in the clinical management of NSCLC.

Small-molecule tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, specifically target epidermal growth factor receptor
(EGFR) and generate much optimism in the treatment of NSCLC. EGFR mutations have been demonstrated to be the strongest predictive biomarkers for the efficacy of EGFR-TKIs [4–8]. Patients with EGFR activating mutations, mainly in-frame deletions in exon 19 (19Del) and L858R substitutions in exon 21, have dramatic tumor responses and favorable survival benefit from EGFR-TKIs [9,10]. However, most responsive patients would eventually experience progressive disease (PD). The secondary T790M mutation in exon 20 accounts for approximately 50% of the mechanism of acquired resistance [11]. Hence, it is of great clinical importance to analyze and track EGFR mutation status for predicting efficacy and monitoring resistance throughout EGFR-TKIs treatment in NSCLC patients.

EGFR mutation analysis is recommended in National Comprehensive Cancer Network clinical guidelines for NSCLC. Nevertheless, a national survey shows that only 9.6% of NSCLC patients with stage IIIb or IV disease had EGFR-related testing performed in China [12]. Partly because tumor tissue, the optimal DNA source for EGFR mutation analysis, is always difficult to obtain. Most NSCLC patients presenting inoperable advanced disease cannot provide surgical samples, whereas biopsy samples may not be sufficient for both pathologic examination and mutation analysis. Besides, many patients refuse repeated biopsy at the time of disease progression. However, peripheral blood of cancer patients frequently contains circulating free DNA (cfDNA) derived from tumor cells, which has been used to detect tumor-specific alterations [13]. Moreover, blood sampling is minimally invasive, readily accessible, relatively repeatable. Thus, using blood for EGFR mutation identification and follow-up shows promise.

Amplification Refractory Mutation System (ARMS) has been extensively used in large clinical trials, and has been proved to be a stable, highly sensitive and specific method for EGFR mutation detection in tumor tissue. This method was shown to be able to detect mutations in samples containing as little as 1% mutated DNA [4,14–16]. In this study ARMS was used to detect EGFR mutations in plasma, serum and tumor tissue samples of NSCLC patients. The objective of this study was to determine the feasibility and predictive utility of EGFR mutation detection in blood.

Patients and Methods

Patients

To be eligible for this study, patients were required to have pathologically confirmed NSCLC and available plasma, serum or tumor tissue for EGFR mutation analysis. 164 patients were enrolled in this study from October 2011 to October 2012 at Shanghai Pulmonary Hospital. Patients’ clinicopathologic characteristics, treatment regimens, tumor responses and survival outcomes were recorded. Smoking history was based on records at patients’ first clinic visit and having smoked more than 100 cigarettes in a lifetime was used to define smokers. Performance status was evaluated using the Eastern Cooperative Oncology Group criteria. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumours guidelines. Written informed consent was obtained from all participants, and provision of plasma, serum and tumor tissue for EGFR mutation analysis was optional. This study was approved by the Institutional Ethics Committee of Shanghai Pulmonary Hospital.

Sample Collection

Plasma was collected from 141 patients and serum from 108 patients. Plasma/serum was separated from 4 mL peripheral blood by centrifugation at 1,000 rpm for 10 min at 4°C within 4 hours after collection and stored at -80°C until DNA extraction. Tumor tissue obtained from 142 patients via biopsy was put into RNAlater solution (Ambion, Austin, Texas, USA) and stored at -80°C until DNA extraction. All tumor tissue samples went through pathologic evaluation to confirm the diagnosis of NSCLC.

DNA Extraction

DNA was extracted from 1 ml plasma/serum or 2-20 mg tumor tissue. The DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) was used to extract DNA according to the manufacturer’s instructions. The concentration and purity of DNA were determined by NanoDrop 2000 Spectrophotometer (Thermo Scientific, Waltham, USA). DNA extracted from tumor tissue was standardized to 1 ng/μL, whereas cfDNA extracted from plasma/serum was used for EGFR mutation analysis immediately without standardization.

EGFR Mutation Analysis

The Human EGFR Gene Mutations Fluorescence Polymerase Chain Reaction Diagnostic Kit (Amoy Diagnostics, Xiamen, China), which is based on ARMS technology, was used to detect the 19Del, L858R and T790M mutation according to the manufacturer’s instructions. Briefly, all reactions were performed in 25 μL volumes including 4.7 μL of template DNA, 0.3 μL of Taq polymerase and 20 μL of reaction buffer mix. Real-time PCR was carried out using MX3000P real-time PCR machine (Stratagene, La Jolla, CA, USA) under following conditions: (1) initial denaturation at 95°C for 5 min, (2) 15 cycles of 95°C 25 s, 64°C 20 s and 72°C 20 s, (3) 31 cycles of 93°C 25 s, 60°C 35 s and 72°C 20 s with fluorescence FAM and HEX reading at 60°C of each cycle in phase 3. Data analysis was performed with MxPro v4.10 (Stratagene, La Jolla, CA, USA). Cycle threshold (Ct) represents the threshold at which the signal was detected above background fluorescence. ΔCt values were calculated as the difference between the mutation Ct and control Ct. Positive results were defined as follows: (1) Ct is lower than 26, (2) Ct is higher than 26 and ΔCt is lower than the cut-off ΔCt value (11 for 19Del and L858R, 7 for T790M).

Statistical Analysis

SPSS statistical software, version 17.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. The comparison of EGFR mutation rate among different sample types and the correlation between EGFR mutation status and clinicopathologic characteristics as well as response to EGFR-TKIs were evaluated using Chi-square test or Fisher’s exact test. Cohen’s kappa statistic and McNemar’s test were used to analyze the concordance of EGFR mutation status between matched samples. Progression-free survival (PFS) with EGFR-TKIs treatment according to EGFR mutation status was estimated by Kaplan-Meier method and compared using log-rank test. A two-sided P value less than 0.05 indicated statistical significance.

Results

Patient Characteristics

In total, 164 Chinese patients with NSCLC were enrolled in this study from October 2011 to October 2012 at Shanghai Pulmonary Hospital.
Hospital and their clinicopathologic characteristics are listed in Table 1. During this study, 96 patients didn’t receive EGFR-TKIs, 19 received EGFR-TKIs as first-line therapy, 32 as second-line therapy and 17 as third-line or subsequent therapy. Of 68 patients who received EGFR-TKIs, 51 had their samples collected before EGFR-TKIs treatment and 17 after PD to EGFR-TKIs.

**EGFR Mutation Status**

A total of 141 plasma samples, 108 serum samples and 142 tumor tissue samples were available for EGFR mutation analysis (Table 2). EGFR mutations were detected in 66 (46.5%) tumor tissue samples, of which 38 samples harbored a 19Del, 27 a L858R and 8 a T790M (concurrent with 19Del in 6 and L858R in one). 36 (25.5%) plasma samples exhibited EGFR mutations, including 22 with 19Del, 14 with L858R and 6 with T790M (concurrent with 19Del in 4 and L858R in one). One plasma sample exhibited both 19Del and L858R. In serum samples, EGFR mutation rate was 22.2%. 24 mutation-positive serum samples included 14 with 19Del, 9 with L858R and 3 with T790M (concurrent with 19Del in 2). EGFR mutation rate was significantly higher in tumor tissue than in plasma (46.5% versus 25.5%, \( P < 0.001 \)) and serum (46.5% versus 22.2%, \( P < 0.001 \)).

**Correlation between EGFR Mutation Status and Clinicopathologic Characteristics**

The correlation between EGFR mutation status and patients’ clinicopathologic characteristics was summarized in Table 3. In tumor tissue, EGFR mutation status was correlated with patients’ gender, smoking history and histology. EGFR mutation rate was significantly higher in females than in males (60.0% versus 36.6%, \( P = 0.006 \)), in never smokers than in smokers (55.4% versus 36.8%, \( P = 0.026 \)) and in patients with adenocarcinoma than in those with other histology (53.7% versus 23.5%, \( P = 0.002 \)). In blood samples, EGFR mutation status was only associated with histology. Patients with adenocarcinoma had significantly higher mutation rate than those with other histology in both plasma (30.0% versus 9.7%, \( P = 0.022 \)) and serum (26.7% versus 4.5%, \( P = 0.024 \)).

**Comparison of EGFR Activating Mutation Status in Different Sample Types**

→ Plasma versus Tumor Tissue

EGFR mutation status was analyzed in 121 patients who provided plasma and matched tumor tissue samples (Table 4). 89 patients had identical EGFR mutation status in both plasma and tumor tissue, including 27 with activating mutations and 62 with wild type. Discrepant mutation results were observed: 29 patients with mutant tumors had no mutation in matched plasma, whereas 3 patients with mutant cfDNA had no mutation in corresponding tumor tissue. The concordance rate of EGFR mutation status between plasma and tumor tissue was 73.6% (89/121). Compared with tumor tissue, the sensitivity and specificity for EGFR mutation detection in plasma by ARMS was 48.2% (27/56) and 95.4% (62/65), respectively. The false negative rate was high: 51.8% (29/56) of patients with EGFR mutant tumor were identified as wild type in plasma.

---

**Table 1. Patient Characteristics.**

| Characteristics | No. of patients (n = 164) | Percentage (%) |
|-----------------|--------------------------|----------------|
| Age (years)     | Median 58                |                |
|                 | Range 32-81              |                |
| Gender          | Female 68                | 41.5           |
|                 | Male 96                  | 58.5           |
| Smoking history | Never smoker 84           | 51.2           |
|                 | Smoker 80                | 48.8           |
| Histology       | Adenocarcinoma 128       | 78             |
|                 | Squamous cell carcinoma 18 | 11            |
|                 | Adenosquamous carcinoma 5 | 3             |
|                 | NSCLC NOS 13             | 8              |
| Stage           | IIIB 14                  | 8.5            |
|                 | IV 131                   | 79.9           |
| Postoperative relapse | 19                | 11.6           |

| Performance Status | 0-1 151 |                 |
|                   | 2 9     | 5.5            |
|                   | 3–4 4   | 2.4            |

NSCLC, non-small cell lung cancer; NOS, not otherwise specified.

---

**Table 2. EGFR Mutation Status.**

| cfDNA EGFR mutation status | Tumor EGFR mutation status | Plasma | Serum |
|----------------------------|---------------------------|--------|-------|
|                            | 19Del only | L858R only | T790M only | 19Del and T790M | L858R and T790M | Wild type | Unknown | Total |
| 19Del only                  | 13         | 0          | 0         | 2          | 0         | 1          | 1          | 17          |
| L858R only                 | 0          | 9          | 0         | 0          | 1         | 1          | 1          | 12          |
| T790M only                 | 0          | 1          | 0         | 0          | 0         | 0          | 0          | 1           |
| 19Del and L858R            | 0          | 0          | 0         | 0          | 0         | 1          | 0          | 1           |
| 19Del and T790M            | 1          | 0          | 0         | 1          | 0         | 4          | 0          | 4           |
| L858R and T790M            | 0          | 1          | 0         | 0          | 0         | 0          | 0          | 1           |
| Wild type                  | 14         | 12         | 1         | 2          | 0         | 61         | 15         | 105         |
| Unknown                    | 4          | 4          | 0         | 1          | 0         | 12         | 2          | 23          |
| Total                      | 32         | 26         | 1         | 6          | 1         | 76         | 22         | 164         |

| cfDNA EGFR mutation status | Tumor EGFR mutation status | Plasma | Serum |
|----------------------------|---------------------------|--------|-------|
|                            | 19Del only | L858R only | T790M only | 19Del and T790M | L858R and T790M | Wild type | Unknown | Total |
| 19Del only                  | 7          | 0          | 0         | 3          | 0         | 1          | 1          | 12          |
| L858R only                 | 0          | 6          | 0         | 0          | 1         | 1          | 1          | 9           |
| T790M only                 | 0          | 0          | 0         | 0          | 0         | 0          | 1          | 1           |
| 19Del and T790M            | 1          | 0          | 0         | 1          | 0         | 0          | 0          | 2           |
| Wild type                  | 13         | 14         | 0         | 2          | 0         | 41         | 14         | 84          |
| Unknown                    | 11         | 6          | 1         | 0          | 0         | 32         | 6          | 56          |
| Total                      | 32         | 26         | 1         | 6          | 1         | 76         | 22         | 164         |

EGFR, epidermal growth factor receptor; cfDNA, circulating free DNA; Unknown, no sample available.
Serum versus Tumor Tissue

For EGFR mutation analysis, 92 patients provided serum and matched tumor tissue samples (Table 4). 61 patients exhibited identical EGFR mutation status in both serum and tumor tissue, including 19 with activating mutations and 42 with wild type. Discrepant results were observed: 29 patients with mutant tumors had no mutation in corresponding serum, whereas 2 patients with mutant cfDNA had no mutation in matched tumor tissue. The concordance rate of EGFR mutation status between serum and tumor tissue was 66.3% (61/92). Compared with tumor tissue, the sensitivity and specificity of EGFR mutation detection in serum by ARMS was 39.6% (19/48) and 95.5% (42/44), respectively. The false negative rate was high: 60.4% (29/48) of patients with EGFR mutant tumor were identified as wild type in serum.

Plasma versus Serum

94 patients provided plasma and paired serum samples. 82 patients exhibited identical EGFR mutation status in both plasma and serum, including 17 with activating mutations and 65 with wild type. Discordant results were observed: 9 patients had mutant cfDNA in plasma but not in serum, whereas 3 patients had mutant cfDNA in serum but not in plasma. The concordance rate of EGFR mutation status between plasma and serum was 87.2% (82/94). The kappa coefficient of 0.657 was statistically significant (P < 0.001), whereas the McNemar’s test showed no significant difference (P = 0.146).

Comparison of EGFR T790M Mutation Status in Different Sample Types

T790M was detected in 14 (8.5%) patients. Among them, one patient exhibited T790M concurrent with 19Del in matched plasma, serum and tumor tissue, whereas 10 patients had discrepant results between blood and tumor tissue.

Correlation between EGFR Mutation Status and Response to EGFR-TKIs

In 68 patients who received EGFR-TKIs, the correlation between EGFR mutation status and response to EGFR-TKIs was analyzed (Table 5). For tumor tissue, objective response rate (ORR) of patients with or without EGFR activating mutations was 68.4% (26/38) and 10.5% (2/19), respectively (P < 0.001). For plasma samples, ORR of patients with or without EGFR activating mutations was 68.4% (13/19) and 38.9% (14/36), respectively (P = 0.037). For serum samples, ORR of EGFR activating mutation positive and negative patients was 75.0% (12/16) and 39.5% (15/38), respectively (P = 0.017). ORR of patients with EGFR mutant tumor was consistent to that of patients with EGFR mutant cfDNA in plasma (P = 1.000) and serum (P = 0.024), whereas ORR of patients with wild-type tumor was significantly lower than that of patients with wild-type cfDNA in plasma (P = 0.028) and serum (P = 0.024).

Of 17 patients who provided samples after PD to EGFR-TKIs, 9 (52.9%) exhibited T790M concurrent with an EGFR activating mutation. In addition, one patient with L858R in tumor tissue but

| Table 3. Correlation between Clinical Characteristics and EGFR Mutation Status. |
|----------------|----------------|----------------|----------------|
| Characteristic | Tumor tissue (n = 142) | Plasma (n = 141) | Serum (n = 108) |
|                | Mutation | Wild type | P values | Mutation | Wild type | P values | Mutation | Wild type | P values |
| Age            |          |          |          |          |          |          |          |          |          |
| ≥65 years      | 13       | 20       | 0.352    | 6        | 27       | 0.269    | 3        | 23       | 0.133    |
| <65 years      | 53       | 56       |          | 30       | 78       |          | 21       | 61       |          |
| Gender         |          |          | 0.006    |          | 0.790    |          |          |          | 0.877    |
| Female         | 36       | 24       |          | 16       | 44       |          | 11       | 37       |          |
| Male           | 30       | 52       |          | 20       | 61       |          | 13       | 47       |          |
| Smoking history|          |          | 0.026    |          | 0.136    |          |          |          | 0.108    |
| Never          | 41       | 33       |          | 23       | 52       |          | 17       | 44       |          |
| Current/former | 25       | 43       |          | 13       | 53       |          | 7        | 40       |          |
| Histology      |          |          | 0.002    |          | 0.022    |          |          |          | 0.024    |
| Adenocarcinoma | 58       | 50       |          | 33       | 77       |          | 23       | 63       |          |
| Non-adenocarcinoma | 8     | 26       |          | 3        | 28       |          | 1        | 21       |          |
| Stage I/II-IV  |          |          | 0.445    |          | 0.831    |          |          |          | 0.061    |
| Postoperative replayer | 6 | 10 |          | 3        | 10       |          | 0        | 11       |          |
| Performance Status |          |          | 0.724    |          | 0.729    |          |          |          | 1.000    |
| 0-1            | 63       | 71       |          | 34       | 96       |          | 22       | 76       |          |
| ≥2             | 3        | 5        |          | 2        | 9        |          | 2        | 8        |          |

EGFR, epidermal growth factor receptor.

| Table 4. Comparison of EGFR Activating Mutation Status in Different Sample Types. |
|----------------|----------------|----------------|----------------|
| Sample         | Tumor tissue | Total | Concordance rate | Kappa coefficient | McNemar’s test | Sensitivity | Specificity | False positive rate | False negative rate | PPV | NPV |
| Mutation       | 27           | 30    | 75.6%          | 0.450 (P < 0.001) | P < 0.001    | 48.2%      | 95.4%       | 4.6%       | 51.8%       | 90.0% | 68.1% |
| Wild type      | 29           | 91    | 66.3%          | 0.342 (P < 0.001) | P < 0.001    | 39.6%      | 95.5%       | 4.5%       | 60.4%       | 90.5% | 59.2% |
| Plasma         | 56           | 121   |                |                  |              |            |            |            |            |      |     |
| Mutation       | 19           | 21    |                |                  |              |            |            |            |            |      |     |
| Wild type      | 29           | 71    |                |                  |              |            |            |            |            |      |     |
| Serum          | 48           | 92    |                |                  |              |            |            |            |            |      |     |

EGFR, epidermal growth factor receptor; PPV, positive predictive value; NPV, negative predictive value.
T790M in plasma before EGFR-TKIs treatment directly experienced PD after 1.4 months.

**Correlation between EGFR Mutation Status and Survival**

The correlation between *EGFR* mutation status and median PFS time in patients treated with EGFR-TKIs was assessed. For tumor tissue, PFS for patients with or without *EGFR* activating mutations was 13.6 months (95% confidence interval [CI], 9.9 to 17.3) and 2.1 months (95% CI, 0.8 to 3.4), respectively. The difference was statistically significant (*P* < 0.001, Figure 1A). For plasma samples, patients with *EGFR* activating mutations had a PFS of 7.9 months (95% CI, 1.6 to 14.1) compared with 6.1 months (95% CI, 2.7 to 9.6) for patients with wild-type *EGFR* (*P* = 0.953, Figure 1B). For serum samples, patients harboring *EGFR* activating mutations had a longer PFS of 7.9 months (95% CI, 6.5 to 9.2) than 5.7 months (95% CI, 2.1 to 9.2) for patients without mutations (*P* = 0.889, Figure 1C). Moreover, PFS of patients with *EGFR* mutant tumors was consistent to that of patients with *EGFR* mutant cfDNA in plasma (*P* = 0.094) and serum (*P* = 0.176), whereas PFS of patients with wild-type tumor was significantly shorter than that of patients with wild-type cfDNA in plasma (*P* = 0.023) and serum (*P* = 0.023).

Further, all 68 patients received EGFR-TKIs were stratified into 4 subgroups based on their mutational genotypes: (1) positive for *EGFR* activating mutations in both tumor tissue and blood (*n* = 20), (2) positive for *EGFR* activating mutations in tumor tissue but negative in blood (*n* = 18), (3) positive for *EGFR* activating mutations in blood but negative in tumor tissue (*n* = 4), and (4) negative for *EGFR* activating mutations in both tumor tissue and blood (*n* = 26). PFS for each group was graphed in Figure 1D. Patients in subgroup two had a favorable PFS of 19.7 months (95% CI, 11.5 to 28.0), compared with 11.0 months (95% CI, 3.1 to 19.0) of those in subgroup one (*P* = 0.102) and 1.7 (95% CI, 0.9 to 2.5) months of those in subgroup three (*P* < 0.001). Patients in subgroup four had a comparable PFS of 2.3 months (95% CI, 0.3 to 4.3) with those in subgroup three (*P* = 0.508).

**Discussion**

*EGFR* mutation analysis is recommended in clinical practice to direct personalized management for NSCLC patients. This study demonstrates the possibility of using blood to detect *EGFR* mutations, though tumor tissue remains the best sample.

**Table 5.** Correlation between *EGFR* Activating Mutation Status and Response To EGFR-TKIs.

| Sample   | *EGFR* activating mutation status | CR + PR | SD + PD | Total |
|----------|----------------------------------|---------|---------|-------|
| Tumor Tissue | Mutation                       | 26      | 12      | 38    |
|           | Wild type                       | 2       | 17      | 19    |
|           | Total                           | 28      | 29      | 57    |
| Plasma   | Mutation                       | 13      | 6       | 19    |
|           | Wild type                       | 14      | 22      | 36    |
|           | Total                           | 27      | 28      | 55    |
| Serum    | Mutation                       | 12      | 4       | 16    |
|           | Wild type                       | 15      | 23      | 38    |
|           | Total                           | 27      | 27      | 54    |

*EGFR*, epidermal growth factor receptor; CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive Disease.

**Figure 1.** Progression-free survival (PFS) curves for 68 patients treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A, PFS by *EGFR* activating mutation status in tumor tissue. B, PFS by *EGFR* activating mutation status in plasma. C, PFS by *EGFR* activating mutation status in serum. D, PFS by *EGFR* activating mutation status in both tumor tissue and blood samples. M+, positive for *EGFR* activating mutations; M-, negative for *EGFR* activating mutations.
The concordance of *EGFR* mutation status between blood and tumor tissue has been reported to be varying from 58.3% to 93.1%, with minimal false positive rate and variable false negative rate [17–21]. This study showed that compared with matched tumor tissue the concordance rate in plasma and serum was 73.6% and 66.3%, respectively. ARMS for *EGFR* mutation detection in cfDNA showed low sensitivity but high specificity. High specificity led to low false positive rate, suggesting that *EGFR* mutations identified in blood may be highly predictive of identical mutations in corresponding tumor. Low sensitivity caused high false negative rate, which was responsible for the significantly lower *EGFR* mutation rate in blood compared with tumor tissue. Thus, *EGFR* mutation-negative results in blood should be interpreted with caution as more than half of patients with *EGFR* mutant tumors were not detected in cfDNA by ARMS.

It is notable that 41 patients with mutant tumors had no detectable *EGFR* mutations in matched blood samples. This phenomenon has been observed in previous studies [18,22,23]. The trace amount and low percentage of mutant cfDNA could be below the detection limit of ARMS, giving rise to false negative results in blood. Another possible explanation is that prolonged storage of blood samples resulted in a decrease in the quantity of DNA extracted, thus affecting *EGFR* mutation detection [24]. In contrast, 5 patients with mutant cfDNA had no corresponding mutations in matched tumor tissue. This phenomenon has also been reported and could be explained by tumor heterogeneity: these biopsied tumor tissue samples may not carry the *EGFR* mutations detected in blood, because these mutations come from different parts of the tumor [25–27]. However, 4 of these 5 patients received EGFR-TKIs and had a comparable PFS with those who exhibited wild type in both blood and tumor tissue, suggesting that these mutations detected in blood could be false positive results.

There have been a limited number of studies on the correlation between *EGFR* mutation status in cfDNA and efficacy of EGFR-TKIs [28–32]. Though the researchers tend to agree that *EGFR* activating mutations in cfDNA may be predictive of better response to EGFR-TKIs, they are still uncertain whether *EGFR* mutation status in cfDNA can predict survival benefit from EGFR-TKIs. In a subgroup analysis of IPASS, ORR was 75.0% (18/24) and 27.1% (19/70) with gefitinib in patients with or without *EGFR* mutant cfDNA, respectively. PFS was significantly longer with gefitinib than carboplatin/paclitaxel in the cfDNA mutant subgroup (hazard ratio [HR], 0.29; 95% CI, 0.14–0.60; P < 0.001) but not in the cfDNA wild-type subgroup (HR, 0.88; 95% CI, 0.61–1.28; P = 0.50) [22]. Xu et al. reported that an significant correlation between *EGFR* mutation status in plasma and tumor response to gefitinib was observed using ARMS but not denaturing high-performance liquid chromatography (DHPLC), whereas no association between *EGFR* mutation status in plasma and PFS or overall survival (OS) was observed no matter using ARMS or DHPLC [33]. Bai et al. detected *EGFR* mutations in plasma using DHPLC and found that about 62.2% of patients with *EGFR* mutations responded to gefitinib, whereas 37.8% of patients with wild-type *EGFR* also responded. They noted that patients with *EGFR* mutant cfDNA had a significantly longer PFS than those with wild-type cfDNA (11.1 months versus 5.9 months, P = 0.044), though no difference in OS was seen [25].

In the current study, patients with *EGFR* activating mutations in tumor tissue had significantly greater ORR and longer PFS with EGFR-TKIs, which accords with the finding of previous clinical trials [4–8]. Patients harboring *EGFR* activating mutations in cfDNA also had significantly higher ORR, which was consistent to that of patients with mutant tumors. In addition, patients with mutant cfDNA tended to have longer PFS than those with wild-type cfDNA, though the difference was not significant. These data suggest that *EGFR* activating mutations detected in blood may be predictive of improved tumor response and survival benefit from EGFR-TKIs. But patients with wild-type cfDNA had significantly higher ORR and longer PFS than those with wild-type tumors due to the presence of false negative results, suggesting that *EGFR* mutation-negative results detected in blood by ARMS is inferior to that in tumor tissue with respect to predicting clinical outcomes.

This study showed that in patients with *EGFR* mutant tumors those with wild-type cfDNA tended to have prolonged PFS compared with patients harboring corresponding mutant cfDNA. Similarly, a subgroup analysis of EURTAC indicated that in European patients with advanced *EGFR* mutation-positive NSCLC who received erlotinib as first-line therapy, the presence of mutant cfDNA in serum was associated with reduced PFS (HR, 0.48; 95% CI, 0.22–0.97; P = 0.04) and OS (HR, 0.46; 95% CI, 0.25–0.84; P = 0.02) [34]. For patients who provided pretreatment samples, the presence of *EGFR* mutations in blood may correlate with severe tumor burden, which contributes to higher proportion of tumor-derived cfDNA. Zhao et al. and Zhang et al. found that there were more detectable *EGFR* mutations in plasma from patients with advanced disease or patients with poorly differentiated tumors [21,35]. Park et al. reported that tumor burden was predictive of inferior survival in NSCLC patients with *EGFR* mutant tumor who received gefitinib [36]. For patients who provided posttreatment samples, therapy-related *EGFR* mutation status shift from mutation to wild type may correlate with better response, thus affecting survival benefit. Yung et al. found that plasma concentrations of *EGFR* mutations could decline to undetectable level after EGFR-TKIs treatment in responsive patients [23]. Besides, Bai et al. reported that patients whose *EGFR* mutation status in cfDNA changed from mutant state to wild type after chemotherapy had significantly better clinical response [37]. Dowson et al. demonstrated that cfDNA could provide the earliest measure of treatment response [38]. Hence, serial changes of *EGFR* mutation status in cfDNA during follow-up period could be informative in monitoring treatment response and predicting survival benefit. However, novel ultrasensitive methods would be preferable, so that smaller changes in cfDNA mutation status can be monitored in a better way.

The secondary T790M mutation has been reported to be present in about half of NSCLC patients with acquired resistance to EGFR-TKIs and is usually concurrent with activating mutations, which is consistent with this study [39]. Rosell et al. and Su et al. reported that patients with T790M-positive tumors before EGFR-TKIs treatment had a shorter PFS than those having T790M-negative tumors [40,41]. In this study one patient, with L858R in tumor tissue but T790M-positive cfDNA who received erlotinib as first-line therapy, the presence of mutant cfDNA in serum was associated with reduced PFS (HR, 0.48; 95% CI, 0.22–0.97; P = 0.04) and OS (HR, 0.46; 95% CI, 0.25–0.84; P = 0.02) [34]. These data suggest that T790M mutations in cfDNA may aid in monitoring resistance and predicting efficacy of EGFR-TKIs.

There were several limitations of this study. The sample size was relatively small and samples were not well matched. Besides, this study was not specifically designed to evaluate EGFR-TKIs treatment. Notwithstanding its limitations, this study demonstrates that *EGFR* mutations detected in blood of NSCLC patients by ARMS may be highly predictive of identical mutations in...
corresponding tumor, as well as showing correlations with tumor response and survival benefit from EGFR-TKIs. However, due to the method’s low sensitivity in blood samples, tumor tissue remains the best sample for EGFR mutation analysis. Further investigations involving appropriate methodologies to decrease false negatives in cfDNA-based EGFR mutation analysis are warranted.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (No.81172101) and the key project of the Science and Technology Commission of Shanghai Municipality (No.11JC1411301).

No conflicts of interests are present.

The authors are grateful to all the patients and investigators for their participation in this study.

References

[1] Siegel R, Naishadham D, and Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin 63, 11–30.

[2] Molina JR, Yang P, Cassivi SD, Schild SE, and Adjei AA (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584–594.

[3] Travis WD, Brambilla E, and Roly GJ (2013). New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31, 992–1001.

[4] Fukushima M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Srijanprasert V, Chao YY, Nakagawa K, Chu DT, and Saji N, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 29, 2866–2874.

[5] Zhou C, Wu YL, Chen G, Feng J, Liu QX, Wang C, Zhang S, Wang J, Zhou S, and Ren S, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non–small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12, 735–742.

[6] Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, and Lu S, et al (2011). Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non–small-cell lung cancer (INFORM: CTONG-0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 13, 466–475.

[7] Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, and Kim BS, et al (2012). Gefitinib versus pemetrexed as second-line treatment in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer 118, 6234–6242.

[8] Garassino MC, Martelli O, Brogini M, Farina G, Veronesi S, Rulli E, Bianchi F, Bettini A, Longo F, and Moscetti L, et al (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non–small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14, 981–988.

[9] Santarpia M, Altavilla G, Salazar MF, Magri I, Petinone G, Benecchi S, and Rosell R (2011). Tyrosine kinase inhibitors for non–small-cell lung cancer: finding patients who will be responsive. Expert Rev Respir Med 5, 413–424.

[10] Gazdar AF (2009). Activating and resistance mutations of EGFR in non–small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 29, 5243–531.

[11] Engelland JA and Jinne PA (2008). Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer. Clin Cancer Res 14, 2895–2899.

[12] Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, Zhao H, Wu J, Zhang Y, and Zhao L, et al (2012). National survey of the medical treatment status for non–small cell lung cancer (NSCLC) in China. Lung Cancer 77, 371–375.

[13] Brennes RM, Sirera R, and Camps C (2005). Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49, 1–12.

[14] Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, and Archer V, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non–small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537.

[15] Zhu C-Q, da Cunha Santos G, Ding K, Sakurada A, Cuz JC, Liu N, Zhang T, Marrano P, Whitehead M, and Squire JA, et al (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26, 4628–4675.

[16] Pao W and Ladanyi M (2007). Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13, 4954–4955.

[17] Kimura H, Kasahara K, Shiibata K, Sone T, Yoshimoto A, Kita T, Ichikawa Y, Waseda Y, Watanabe K, and Shirazaki H, et al (2006). EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non–small-cell lung cancer. J Thorac Oncol 1, 260–267.

[18] Kimura H, Kasahara K, Kawai M, Kunii H, Tamura T, Holloway B, and Nishio K (2006). Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non–small-cell lung cancer. Clin Cancer Res 12, 3915–3921.

[19] Jiang B, Liu F, Yang L, Zhang W, Yuan H, Wang J, and Huang G (2011). Serum detection of epidermal growth factor receptor gene mutations using mutant–enriched sequencing in Chinese patients with advanced non–small cell lung cancer. J Int Med Res 39, 1392–1401.

[20] Kim ST, Sung JS, Jo UH, Park KH, Shin SW, and Kim YH (2013). Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non–small cell lung cancer (NSCLC)? Med Oncol 30, 328.

[21] Zhao X, Han RB, Zhao J, Wang J, Yang F, Zhong W, Zhang L, Li LY, and Wang MZ (2013). Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I–IV non–small cell lung cancer patients. Respira 85, 119–125.

[22] Goto K, Ishino Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, and McCormack R, et al (2012). Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non–small cell lung cancer. J Thorac Oncol 7, 115–121.

[23] Yung TK, Chan KC, Mok TS, Tong J, To KF, and Lo YM (2009). Single–molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non–small cell lung cancer patients. Clin Cancer Res 15, 2076–2084.

[24] Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, and Pastorino U (2005). Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 97, 1848–1850.

[25] Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Xuan CJ, Wu NM, and Guo ZQ, et al (2012). Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non–small–cell lung cancer, J Clin Oncol 27, 1850–1859.

[26] Brevet M, Johnson ML, Azzoli CG, and Ladanyi M (2011). Detection of EGFR mutations in plasma DNA from lung cancer patients by microfluidics digital PCR in non–small cell lung cancer patients. J Clin Oncol 29, 4666–4675.

[27] Taniguchi K, Okami J, Kodama K, Higashiyama M, and Kato K (2008). Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99, 929–935.

[28] Kimura H, Suninoo M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, and Fujimura M, et al (2007). Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97, 778–784.

[29] He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, and Xu J (2009). Detection of epidermal growth factor receptor mutations in plasma by mutant–enriched PCR assay for prediction of the response to gefitinib in patients with non–small–cell lung cancer. Int J Cancer 125, 2393–2399.
Liu Y, Liu B, Li XY, Li JJ, Qin HF, Tang CH, Guo WF, Hu HX, Li S, and Chen CJ, et al (2011). A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. *J Exp Clin Cancer Res* **30**, 111.

Chen YM, Fan WC, Tseng PC, Tsai CM, Chou TY, Wu CH, Chou KT, Lee YC, Perng RP, and Whang-Peng J (2012). Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. *Oncol Lett* **3**, 713–717.

Kim ST, Jung HY, Sung JS, Jo UH, Tanaka T, Hagiwara K, Park KH, Shin SW, Kim JS, and Kim YH (2013). Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? *Am J Clin Oncol* **36**, 57–63.

Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, and Xu J, et al (2012). Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. *Onco Targets Ther* **5**, 439–447.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Masutti B,Felip E, Palmero R, Garcia-Gomez R, Pallares C, and Sanchez JM, et al (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* **13**, 239–246.

Zhang L, Yang H, Zhao Y, Liu W, Wu S, He J, Luo X, Zhu Z, Xu J, and Zhou Q, et al (2012). Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology. *Curr Drug Metab* **13**, 1007–1011.

Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, and Heo DS (2013). Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. *Clin Lung Cancer* **14**, 383–389.

Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, and An T, et al (2012). Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. *J Clin Oncol* **30**, 3077–3083.

Dawson SJ, Tsui DW, Mustafa M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Fortihow T, and Mahler-Araujo B, et al (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* **368**, 1199–1209.

Suda K, Onozato R, Yatabe Y, and Mitsudomi T (2009). EGFR T790M mutation: a double role in lung cancer cell survival? *J Thorac Oncol* **4**, 1–4.

Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, and Cardenal F, et al (2011). Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib–treated advanced non-small-cell lung cancer patients with EGFR mutations. *Clin Cancer Res* **17**, 1160–1168.

Su KY, Chen KY, Li KC, Kuo ML, Yang JC, Chen WK, Ho BC, Chang GC, Shih JY, and Yu SL, et al (2012). Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. *J Clin Oncol* **30**, 433–440.

Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, and Yanagitani N, et al (2013). Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. *Cancer Sci* **104**, 1198–1204.